- Companies
- IMBdx
IMBdx Valuation Multiples
IMBdx is valued at $22M as of November 2026, a 2.3x revenue multiple. In the last fiscal year, IMBdx revenue was $4M and IMBdx EBITDA was ($5M).
IMBdx Overview
About IMBdx
IMBdx Inc detects and analyzes the genomic profile of tumor DNA with a single draw of blood. It provides personalized and optimized analysis information that can be utilized in therapy selection and monitoring. Its AlphaLiquid platform offers ctDNA-based precision diagnostics solutions across the full continuum of cancer care, from therapy selection (AlphaLiquid 100/HRR) to recurrence and minimal residual disease(MRD) monitoring (CancerDetect), and multi-cancer early detection (CancerFind). Its services are Clinical Service BioPharma, Research, and Healthcare Checkup.
Founded
2018
HQ
Employees
N/A
Website
Financials (Last FY)
EV
$9M
Valuation Multiples
Start free trialIMBdx Financials
IMBdx reported last fiscal year revenue of $4M and negative EBITDA of ($5M).
In the same fiscal year, IMBdx generated $1M in gross profit, ($5M) in EBITDA losses, and had net loss of ($6M).
IMBdx P&L
In the most recent fiscal year, IMBdx reported revenue of $4M and EBITDA of ($5M).
IMBdx is unprofitable as of last fiscal year, with gross margin of 26%, EBITDA margin of (134%), and net margin of (149%).
Financial data powered by Morningstar, Inc.
IMBdx Stock Performance
IMBdx has current market cap of $22M, and enterprise value of $9M.
Market Cap Evolution
IMBdx's stock price is $1.55.
IMBdx share price decreased by 13.6% in the last 30 days.
IMBdx has an EPS (earnings per share) of $-0.41.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $9M | $22M | -5.5% | -13.6% | -29.8% | - | $-0.41 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialIMBdx Valuation Multiples
IMBdx trades at 2.3x EV/Revenue multiple, and (1.7x) EV/EBITDA.
IMBdx Financial Valuation Multiples
As of November 18, 2026, IMBdx has market cap of $22M and EV of $9M.
IMBdx has a P/E ratio of (3.7x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified IMBdx Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


IMBdx Margins & Growth Rates
In the most recent fiscal year, IMBdx reported gross margin of 26%, EBITDA margin of (134%), and net margin of (149%).
IMBdx Margins
IMBdx Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
IMBdx Operational KPIs
Data powered by FactSet, Inc. and Morningstar, Inc.
IMBdx Competitors
IMBdx competitors include Cheelcare, IMD International Medical, Integrum, Implanet, HeartBeam, aap Implantate, Epitomee Medical, Vivos, Q-linea and Cambridge Cognition.
Most IMBdx public comparables operate across Diagnostics & Genomics, Medical Devices, BioTech and DeepTech.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $1M | ($3M) | 16.5x | - | (7.5x) | - | |||
| $38M | $3M | 0.4x | 0.5x | 6.0x | 5.4x | |||
| $9M | ($3M) | 2.3x | - | (6.1x) | - | |||
| $14M | ($4M) | 2.0x | - | (7.5x) | - | |||
| - | ($21M) | - | - | (0.7x) | - | |||
| $14M | ($871K) | 1.9x | 2.0x | (29.6x) | (11.3x) | |||
| $213K | ($7M) | 97.5x | - | (2.8x) | - | |||
| $68K | ($3M) | 275.4x | - | (6.0x) | - | |||
This data is available for Pro users. Sign up to see all IMBdx competitors and their valuation data. Start Free Trial | ||||||||
IMBdx VC Funding History
Before going public, IMBdx raised $28M in total equity funding, across 3 rounds.
IMBdx Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout IMBdx
| When was IMBdx founded? | IMBdx was founded in 2018. |
| Where is IMBdx headquartered? | IMBdx is headquartered in South Korea. |
| Is IMBdx publicly listed? | Yes, IMBdx is a public company listed on Korea Exchange. |
| What is the stock symbol of IMBdx? | IMBdx trades under 461030 ticker. |
| When did IMBdx go public? | IMBdx went public in 2024. |
| Who are competitors of IMBdx? | IMBdx main competitors include Cheelcare, IMD International Medical, Integrum, Implanet, HeartBeam, aap Implantate, Epitomee Medical, Vivos, Q-linea, Cambridge Cognition. |
| What is the current market cap of IMBdx? | IMBdx's current market cap is $22M. |
| What is the current revenue of IMBdx? | IMBdx's last fiscal year revenue is $4M. |
| What is the current EV/Revenue multiple of IMBdx? | Current revenue multiple of IMBdx is 2.3x. |
| Is IMBdx profitable? | No, IMBdx is not profitable. |
| How many companies IMBdx has acquired to date? | IMBdx hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies IMBdx has invested to date? | IMBdx hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to IMBdx
Lists including IMBdx
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




